Sun Pharmaceutical is currently trading at Rs. 517.30, up by 4.90 points or 0.96% from its previous closing of Rs. 512.40 on the BSE.
The scrip opened at Rs. 518.80 and has touched a high and low of Rs. 523.00 and Rs. 516.40 respectively. So far 5,129 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 539.90 on 05-Dec-2011 and a 52 week low of Rs. 392.05 on 09-Feb-2011.
Last one week high and low of the scrip stood at Rs. 539.90 and Rs. 505.50 respectively. The current market cap of the company is Rs. 53,569.00 crore.
The promoters holding in the company stood at 63.72% while Institutions and Non-Institutions held 25.48% and 10.81% respectively.
Sun Pharmaceutical Industries’ subsidiary has been granted an approval from United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) to market a generic version of Ultram ER, Tramadol hydrochloride extended release tablets.
These generic Tramadol hydrochloride extended release tablets, 100 mg, 200 mg and 300 mg are therapeutically equivalent to Ultram ER tablets of Valeant. These Tramadol HCL ER tablets have annual sales of approximately $125 million in US.
Tramadol HCL ER tablets are indicated for management of moderate to moderately severe chronic pain in adults who need around-the-clock treatment of their pain for an extended period of time.
Sun Pharmaceutical Industries manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1777.65 |
Dr. Reddys Lab | 1194.55 |
Cipla | 1465.65 |
Lupin | 2043.30 |
Zydus Lifesciences | 944.25 |
View more.. |